Scisparc to commence its clinical trial with sci-210 in children with autism spectrum disorder

“we hope the outcome of this trial will enable the company to procced with commercialization process for sci-210 in israel" tel aviv, israel, july 14, 2023 (globe newswire) -- scisparc ltd. (nasdaq: sprc) ("company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted an approval from the israeli medical cannabis agency ("imca") at the israeli ministry of health to conduct its clinical trial for sci-210 in children suffering from autism spectrum disorder ("asd").
SPRC Ratings Summary
SPRC Quant Ranking